market-trends is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Adaptive Biotechnologies, the most common co-covered peer. Susan Bobulsky appears in 1 tracked Healthcare story from March 14, 2026. The tracked stories average 2 original sources each.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Susan Bobulsky
market-trends is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Adaptive Biotechnologies, the most common co-covered peer. Susan Bobulsky appears in 1 tracked Healthcare story from March 14, 2026. The tracked stories average 2 original sources each.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 13 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Susan Bobulsky. Shared-story counts are live from our verified record — not editorial picks.
Adaptive Biotechnologies (NASDAQ: ADPT) executives Julie Rubinstein and Susan Bobulsky have sold a combined 60,398 shares, signaling a notable period of insider liquidation. The transactions occur as the company continues to navigate the competitive landscape of immune-driven diagnostics and MRD monitoring.